Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint

NovoCure Ltd

2023-Q2 EPS reported -$1.04 revenue$248,233,000

Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.
LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).
Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.
Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.
PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NovoCure Ltd reported the quarter ended June 30, 2023 results: revenue $126.1 million, net income $57.4 million, EPS $0.54.

Period: the quarter ended June 30, 2023
Revenue: $126.1 million
Net income: $57.4 million
EPS: $0.54
Result: reported results

Exact text from the filing

30, 2023. A copy of the press release is attached as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Novocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.